This document summarizes Israel's life sciences industry and investment opportunities. Israel has a strong life sciences sector, with the highest civilian R&D spending as a percentage of GDP globally. Key sectors include biotechnology, pharmaceuticals, and medical devices. Israel has developed blockbuster drugs and medical technologies. It also has a robust stem cell research sector. Foreign companies have established R&D centers in Israel to take advantage of the innovative ecosystem and government support programs. The Investment Promotion Center encourages investors to establish operations in Israel to access these opportunities.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
Stryker Corporation develops and markets specialty surgical and medical products worldwide including orthopedic implants, trauma systems, surgical instruments, and rehabilitation equipment. In 2001, Stryker reported net sales of $2.6 billion, a 14% increase over 2000. Net earnings for 2001 were $267 million, a 21% increase over the previous year. Stryker executes its business through 14 divisions focused on product development and international sales. Stryker prides itself on execution, quality, and innovation, which has led to 25 years of 25% annual net earnings growth.
Marcus evans 9th annual commercial translation of regenerative medicine fun...ProteusVenturePartners
This document discusses funding and commercialization strategies for regenerative medicine companies. It notes that while regenerative medicine has made great progress, serious commercialization challenges remain, including developing optimal cells for therapy, manufacturing at scale, addressing regulatory and IP issues, and determining business models. New economic realities require a more capital efficient development model as the "valley of death" between research and commercialization expands. Regenerative medicine translation centers may help enable more efficient technology development and collaborations to address these challenges.
Stem cells usa rm congress cord blood (boston, september 12, 2011)v.1ProteusVenturePartners
This document summarizes Gregory Bonfiglio's presentation on cord blood banking and therapeutics given at Stem Cells USA RM Congress in Boston, Massachusetts. The presentation covers the regenerative medicine market and cord blood market metrics, current cord blood banking practices and therapeutic applications, and therapies using cord blood that are in clinical development, with over 600 ongoing FDA clinical trials.
Proposal for cord blood banking and therapeutics business (roll up strategy ...ProteusVenturePartners
This document proposes building the leading international cryo-banking and stem cell therapeutics company through two phases. Phase I involves acquiring a market leading cord blood bank and rolling up smaller underperforming banks, aggressively marketing to drive revenues and expanding the tissue offering. Phase II brings regenerative medicine therapeutics to emerging markets, initially leveraging stored tissue and addressing unmet regional medical needs with proven therapies. Funding requirements and an exit strategy are also discussed.
Ibc cell therapy clinical development conference (arlington va september 10 ...Proteus Venture Partners
Gregory Bonfiglio presented on why cell therapy clinical trials often fail. The document discussed cell therapy market trends and ongoing clinical trials. It noted that the overall failure rate of FDA clinical trials is 84.7%, with failures occurring most often in phases II and III due to issues with efficacy, safety, and funding. Common reasons cell therapy trials fail include technology failures to demonstrate efficacy or safety, poor clinical trial design, lack of clinical operations experience, inadequate funding, and unresolved regulatory hurdles. The document examined case studies of failed cell therapy trials from Geron and Dendreon.
For more information of how to start up your business
contact me at anapaulaford@yahoo.com
www.anapaulaford.nsedreams.com
www.anapaulaford.nsproducts.com
This document summarizes Israel's life sciences industry and investment opportunities. Israel has a strong life sciences sector, with the highest civilian R&D spending as a percentage of GDP globally. Key sectors include biotechnology, pharmaceuticals, and medical devices. Israel has developed blockbuster drugs and medical technologies. It also has a robust stem cell research sector. Foreign companies have established R&D centers in Israel to take advantage of the innovative ecosystem and government support programs. The Investment Promotion Center encourages investors to establish operations in Israel to access these opportunities.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
Stryker Corporation develops and markets specialty surgical and medical products worldwide including orthopedic implants, trauma systems, surgical instruments, and rehabilitation equipment. In 2001, Stryker reported net sales of $2.6 billion, a 14% increase over 2000. Net earnings for 2001 were $267 million, a 21% increase over the previous year. Stryker executes its business through 14 divisions focused on product development and international sales. Stryker prides itself on execution, quality, and innovation, which has led to 25 years of 25% annual net earnings growth.
Marcus evans 9th annual commercial translation of regenerative medicine fun...ProteusVenturePartners
This document discusses funding and commercialization strategies for regenerative medicine companies. It notes that while regenerative medicine has made great progress, serious commercialization challenges remain, including developing optimal cells for therapy, manufacturing at scale, addressing regulatory and IP issues, and determining business models. New economic realities require a more capital efficient development model as the "valley of death" between research and commercialization expands. Regenerative medicine translation centers may help enable more efficient technology development and collaborations to address these challenges.
Stem cells usa rm congress cord blood (boston, september 12, 2011)v.1ProteusVenturePartners
This document summarizes Gregory Bonfiglio's presentation on cord blood banking and therapeutics given at Stem Cells USA RM Congress in Boston, Massachusetts. The presentation covers the regenerative medicine market and cord blood market metrics, current cord blood banking practices and therapeutic applications, and therapies using cord blood that are in clinical development, with over 600 ongoing FDA clinical trials.
Proposal for cord blood banking and therapeutics business (roll up strategy ...ProteusVenturePartners
This document proposes building the leading international cryo-banking and stem cell therapeutics company through two phases. Phase I involves acquiring a market leading cord blood bank and rolling up smaller underperforming banks, aggressively marketing to drive revenues and expanding the tissue offering. Phase II brings regenerative medicine therapeutics to emerging markets, initially leveraging stored tissue and addressing unmet regional medical needs with proven therapies. Funding requirements and an exit strategy are also discussed.
Ibc cell therapy clinical development conference (arlington va september 10 ...Proteus Venture Partners
Gregory Bonfiglio presented on why cell therapy clinical trials often fail. The document discussed cell therapy market trends and ongoing clinical trials. It noted that the overall failure rate of FDA clinical trials is 84.7%, with failures occurring most often in phases II and III due to issues with efficacy, safety, and funding. Common reasons cell therapy trials fail include technology failures to demonstrate efficacy or safety, poor clinical trial design, lack of clinical operations experience, inadequate funding, and unresolved regulatory hurdles. The document examined case studies of failed cell therapy trials from Geron and Dendreon.
For more information of how to start up your business
contact me at anapaulaford@yahoo.com
www.anapaulaford.nsedreams.com
www.anapaulaford.nsproducts.com
This document provides an overview of Cytori Therapeutics and its cell therapy technology. It discusses Cytori's proprietary process for deriving stem and regenerative cells from a patient's own adipose tissue. It highlights clinical trial results showing benefits of the therapy for heart failure patients. The document also outlines Cytori's business partnerships, including a contract with BARDA to develop the therapy for burns, and revenue opportunities in both international markets and translational research applications. Key milestones for 2013 include completing enrollment in a heart failure trial and advancing the BARDA contract.
On October 12, 2012, Safeguard Scientifics' EVP and Managing Director, Jim Datin presented a case study at the RBC Biotech Conference, which focused on “Biotech Success Stories of the [Philadelphia] Region”. Jim Datin presented a case study on Avid Radiopharmaceuticals, a Safeguard partner company from 2007-2010, when it was acquired by Eli Lilly. The presentation, entitled "“The Success of Avid Pharmaceuticals from an Investor's Point of View" highlights the critical factors to building a great company, "The 5 Ms" -- Management, Market, Model, Momentum and Moat.
Innovations in Medical Devices: Medtronic Advanced EnergyUNHInnovation
Suzanne Foster of Medronic Advanced Energy reviews key challenges faced by Salient Surgical Technologies while being acquired by Medtronic Advanced Energy. Also discussed are overall trends for the medical device industry when it comes to sales, marketing, and innovation.
McKesson Corporation Investor and Analyst Day Presentationfinance2
This document summarizes the agenda and presentations for McKesson's 2006 Investor Day. The agenda included presentations from John Hammergren, Chairman and CEO, Jeff Campbell, EVP and CFO, Paul Julian, EVP, Group President, and Pam Pure, EVP, President of MPT, followed by a Q&A session. McKesson is well-positioned in growing healthcare services markets and has a track record of strong financial performance. It has leading market positions across its Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies segments. Healthcare spending and drug consumption are expected to continue rising driven by demographics, with an aging population requiring more medication.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
This document discusses new technologies for quality control and selection of stem cells for applications in regenerative medicine and cell therapy. It notes that the stem cell quality control and production market is growing rapidly and will be over $1.3 billion by 2018. A novel method is presented for tag-less isolation and sorting of living stem cells, with exclusive features like no cell manipulation, high purity, high cell recovery, and real-time monitoring. The company developing this technology is seeking marketing, sales, business scale-up, and investment partners to help bring their Celector product to market.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
Parallel Session 1.1 Technology Innovation in NHSScotland: The Big DebateNHSScotlandEvent
This document discusses technology innovation in NHS Scotland. It explores different types of technologies including bio, information, communication, device, and pharmaceutical technologies. It defines innovation and shows a spectrum from sustaining to disruptive innovation. It notes that healthcare has been a slow adopter of technology. Studies show telehealth can reduce A&E visits, admissions, and mortality if used correctly. Issues around procurement, the healthcare market, and enabling staff and patients to change are discussed.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
This document summarizes Israel's life sciences industry and aims to promote investment in Israel. It highlights that Israel has a strong innovation ecosystem in life sciences, with the highest civilian R&D spending as a percentage of GDP. Israel also leads in areas like medical device and biopharma patents per capita. The document outlines Israel's competitive advantages and provides statistics on economic growth, exports, unemployment and foreign investment. It summarizes the main sectors and technologies within Israel's life sciences industry, including blockbuster drugs developed, major therapeutic areas and examples of medical device and biotechnology innovations. The conclusion encourages investors to establish operations in Israel and take advantage of government support programs.
This document summarizes a presentation on labor rights and environmental justice in the global electronics industry. It discusses the history of organizing among electronics workers to improve safety and health conditions, including early groups like ECOSH and ongoing issues like chemical exposures, pollution, and higher rates of cancers and birth defects. It notes that workplace exposure limits for carcinogens and toxins are much weaker than environmental standards. The movement has expanded as the industry has moved manufacturing overseas, where new problems have emerged regarding e-waste and occupational illnesses in Asia.
Harris & Harris Group invests in transformative companies developing disruptive science and technology. It has a portfolio of 26 companies across various sectors including life sciences, electronics, and energy. Recent liquidity events from companies like Xradia that was acquired by Carl Zeiss have generated gains. The company aims to continue realizing value from its portfolio through partnerships and exits over the next few years to drive further growth.
The document discusses the growing stem cell industry in India and opportunities for business. It states that the stem cell market in India is expected to reach $540 million by 2010, growing at 15% annually. It highlights that over 500 clinical trials using stem cells are being conducted worldwide to develop new therapies. In India, several public and private hospitals and companies are conducting stem cell therapy trials for various diseases. The document advocates that to succeed in this emerging field, one should provide a complete range of stem cell services including banking, therapies, marketing support, and clinical research organization services.
Technology Commercialization - Biomed2010Cybera Inc.
This document summarizes the experience of a technology company developing digital radiography products. It describes the technology, timeline of development, struggles with setbacks and competing technologies. Key lessons learned include trusting the right team, contingency planning, building an active board, knowing when to let go, and protecting intellectual property. Barriers to entry have decreased over time with falling costs and easier access to information, while the need for financing, hard work and speed remain important.
This document discusses forward-looking statements and contains three key points:
1) It cautions readers that certain information in the presentation constitutes "forward-looking statements" which are inherently uncertain and subject to significant risks and uncertainties.
2) It notes that the forward-looking statements are based on a number of assumptions that may prove to be incorrect, including assumptions about metal prices, exchange rates, production levels, costs, and timelines.
3) It disclaims any obligation to update forward-looking statements except as required by law, and warns readers not to put undue reliance on such statements due to their inherent uncertainty.
The presentation discusses Agile Contents' multimedia solutions for content production and audience engagement. It provides an overview of the enterprise content management, web content management, and online video platform markets. Agile Contents aims to be among the top 10 technology providers in digital media worldwide and has expanded internationally through organic growth and acquisitions to diversify geographically and resume growth.
1) India is emerging as an attractive destination for outsourcing clinical research due to its large patient pools, low costs, and trained workforce.
2) The clinical research industry in India has grown significantly in recent years and is expected to grow from $100 million in 2004 to over $300 million by 2010.
3) India offers many advantages over other countries for clinical trials including lower costs, treatment-naïve patients, and investigators trained in Western practices.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
This document provides an overview of Cytori Therapeutics and its cell therapy technology. It discusses Cytori's proprietary process for deriving stem and regenerative cells from a patient's own adipose tissue. It highlights clinical trial results showing benefits of the therapy for heart failure patients. The document also outlines Cytori's business partnerships, including a contract with BARDA to develop the therapy for burns, and revenue opportunities in both international markets and translational research applications. Key milestones for 2013 include completing enrollment in a heart failure trial and advancing the BARDA contract.
On October 12, 2012, Safeguard Scientifics' EVP and Managing Director, Jim Datin presented a case study at the RBC Biotech Conference, which focused on “Biotech Success Stories of the [Philadelphia] Region”. Jim Datin presented a case study on Avid Radiopharmaceuticals, a Safeguard partner company from 2007-2010, when it was acquired by Eli Lilly. The presentation, entitled "“The Success of Avid Pharmaceuticals from an Investor's Point of View" highlights the critical factors to building a great company, "The 5 Ms" -- Management, Market, Model, Momentum and Moat.
Innovations in Medical Devices: Medtronic Advanced EnergyUNHInnovation
Suzanne Foster of Medronic Advanced Energy reviews key challenges faced by Salient Surgical Technologies while being acquired by Medtronic Advanced Energy. Also discussed are overall trends for the medical device industry when it comes to sales, marketing, and innovation.
McKesson Corporation Investor and Analyst Day Presentationfinance2
This document summarizes the agenda and presentations for McKesson's 2006 Investor Day. The agenda included presentations from John Hammergren, Chairman and CEO, Jeff Campbell, EVP and CFO, Paul Julian, EVP, Group President, and Pam Pure, EVP, President of MPT, followed by a Q&A session. McKesson is well-positioned in growing healthcare services markets and has a track record of strong financial performance. It has leading market positions across its Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies segments. Healthcare spending and drug consumption are expected to continue rising driven by demographics, with an aging population requiring more medication.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
This document discusses new technologies for quality control and selection of stem cells for applications in regenerative medicine and cell therapy. It notes that the stem cell quality control and production market is growing rapidly and will be over $1.3 billion by 2018. A novel method is presented for tag-less isolation and sorting of living stem cells, with exclusive features like no cell manipulation, high purity, high cell recovery, and real-time monitoring. The company developing this technology is seeking marketing, sales, business scale-up, and investment partners to help bring their Celector product to market.
Cytori Therapeutics is a leader in cell therapy with 57 issued patents and 75 pending. Their Celution device is approved in the EU for tissue ischemia and wounds. The company is conducting a US trial called ATHENA to assess the safety and feasibility of using adipose-derived regenerative cells to treat refractory heart failure. Cytori is also partnering with BARDA to develop their next generation Celution system and conduct proof-of-concept studies for burn treatments. Cytori aims to accelerate revenue growth and achieve profitability through expanding commercial sales and translational medicine programs.
Parallel Session 1.1 Technology Innovation in NHSScotland: The Big DebateNHSScotlandEvent
This document discusses technology innovation in NHS Scotland. It explores different types of technologies including bio, information, communication, device, and pharmaceutical technologies. It defines innovation and shows a spectrum from sustaining to disruptive innovation. It notes that healthcare has been a slow adopter of technology. Studies show telehealth can reduce A&E visits, admissions, and mortality if used correctly. Issues around procurement, the healthcare market, and enabling staff and patients to change are discussed.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
This document summarizes Israel's life sciences industry and aims to promote investment in Israel. It highlights that Israel has a strong innovation ecosystem in life sciences, with the highest civilian R&D spending as a percentage of GDP. Israel also leads in areas like medical device and biopharma patents per capita. The document outlines Israel's competitive advantages and provides statistics on economic growth, exports, unemployment and foreign investment. It summarizes the main sectors and technologies within Israel's life sciences industry, including blockbuster drugs developed, major therapeutic areas and examples of medical device and biotechnology innovations. The conclusion encourages investors to establish operations in Israel and take advantage of government support programs.
This document summarizes a presentation on labor rights and environmental justice in the global electronics industry. It discusses the history of organizing among electronics workers to improve safety and health conditions, including early groups like ECOSH and ongoing issues like chemical exposures, pollution, and higher rates of cancers and birth defects. It notes that workplace exposure limits for carcinogens and toxins are much weaker than environmental standards. The movement has expanded as the industry has moved manufacturing overseas, where new problems have emerged regarding e-waste and occupational illnesses in Asia.
Harris & Harris Group invests in transformative companies developing disruptive science and technology. It has a portfolio of 26 companies across various sectors including life sciences, electronics, and energy. Recent liquidity events from companies like Xradia that was acquired by Carl Zeiss have generated gains. The company aims to continue realizing value from its portfolio through partnerships and exits over the next few years to drive further growth.
The document discusses the growing stem cell industry in India and opportunities for business. It states that the stem cell market in India is expected to reach $540 million by 2010, growing at 15% annually. It highlights that over 500 clinical trials using stem cells are being conducted worldwide to develop new therapies. In India, several public and private hospitals and companies are conducting stem cell therapy trials for various diseases. The document advocates that to succeed in this emerging field, one should provide a complete range of stem cell services including banking, therapies, marketing support, and clinical research organization services.
Technology Commercialization - Biomed2010Cybera Inc.
This document summarizes the experience of a technology company developing digital radiography products. It describes the technology, timeline of development, struggles with setbacks and competing technologies. Key lessons learned include trusting the right team, contingency planning, building an active board, knowing when to let go, and protecting intellectual property. Barriers to entry have decreased over time with falling costs and easier access to information, while the need for financing, hard work and speed remain important.
This document discusses forward-looking statements and contains three key points:
1) It cautions readers that certain information in the presentation constitutes "forward-looking statements" which are inherently uncertain and subject to significant risks and uncertainties.
2) It notes that the forward-looking statements are based on a number of assumptions that may prove to be incorrect, including assumptions about metal prices, exchange rates, production levels, costs, and timelines.
3) It disclaims any obligation to update forward-looking statements except as required by law, and warns readers not to put undue reliance on such statements due to their inherent uncertainty.
The presentation discusses Agile Contents' multimedia solutions for content production and audience engagement. It provides an overview of the enterprise content management, web content management, and online video platform markets. Agile Contents aims to be among the top 10 technology providers in digital media worldwide and has expanded internationally through organic growth and acquisitions to diversify geographically and resume growth.
1) India is emerging as an attractive destination for outsourcing clinical research due to its large patient pools, low costs, and trained workforce.
2) The clinical research industry in India has grown significantly in recent years and is expected to grow from $100 million in 2004 to over $300 million by 2010.
3) India offers many advantages over other countries for clinical trials including lower costs, treatment-naïve patients, and investigators trained in Western practices.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g.
Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies
1. Funding & Commercialization Strategies for
Regenerative Medicine Companies
Gregory A. Bonfiglio
Proteus Venture Partners"
November 15, 2011 "
2. Agenda
I. The RM Market Is Entering A New Era
§ RM Has Made Great Progress
§ But Serious Commercialization Challenges Remain
II. New Economic Realties
§ A Fundamental Shift in Biotech Economics
§ The Valley of Death Is Expanding
§ A New Capital Efficient Model Is Required
II. The Role of RM Translation Centers
§ Enabling Capital Efficient RM Technology Development
§ Facilitating Collaborations in RM Technology Development
§ The RMC: An International Coalition of RMTCs
CONFIDENTIAL 2
3. Gartner’s Hype Cycle of Emerging Technologies
Visibility"
Technology Peak of Inflated Trough of Slope of Plateau of Productivity
Trigger Expectations Disillusionment Enlightment
Time"
CONFIDENTIAL 3
4. RM Market: On 2nd Half of the Gartner Curve
Visibility" Peak of Inflated Trough of Slope of Plateau of
Expectations" Disillusionment" Enlightment" Productivity"
2001: 3300 jobs, 73 firms, mkt cap > $2.5B"
2011 Shire Acquires ABH -$750M "
2001 Ortec FDA approved"
2000 Time Magazine: 2010 Cephalon & Mesoblast $2B Deal"
TE No. 1 job"
2001 Dermagraft FDA approved"
2010 Dendreon’s Provenge Approved"
1999 TE bladders in clinic" 2001 Bush “partial ban” on HESCs"
1999 First FDA approved 2009 Obama Ends Ban on hESCs"
TE product (Apligraf)"
1998 Human ESCs first derived" Nov 2008 Genzyme-Osiris $1.25B Deal"
1997 Dolly the sheep" 2007 iPS Technology Developed "
1997 First FDA approved cell
therapy (Carticel)" 2007 Apligraf - 200,000 Patients Treated"
2006 Carticel - 10,000 Patients Treated"
2002 ISSCR Founded"
1992 Geron founded"
2005 CIRM Founded"
1988 SyStemix founded"
1986 ATS and Organogenesis founded" 2003 UK Stem Cell Bank Formed"
1980 Early TE research (MIT)" 2002 ATS + Organogenesis file"
Chapter 11"
Technology Trigger"
Stage of Development" Time"
CONFIDENTIAL 4
5. RM Is Entering A New ERA
RM Market is Maturing: Key Metrics
Rapidly Expanding Market: Commercial Products
• $1.6B in 2010 • 400 on Market (Mostly Skin, Tools
Media, & Devices);
• $20.0B in 2025 – 900+ in Development
• CAGR of 18.34% • 44 Cell Therapies on Market
– $1B Revenues
Dramatic Revenue Growth – 400 in Development
• $130M in 2001 – 28 in PIII/Pivotal Trials
• $1.6B+ in 2010
1.2M+ Patients Treated with RM
Products.
Worldwide funding for research
Increasing • 320K+ Cell Therapy Patients
• $2.5B Now RM Companies
• $14B in 10 Years • 600+ Co’s involved in RM
• 50+ Public Co’s;
Clinical Programs
• Over 3600 Clinical Trials
– $8.7B Total Market Cap
• Over 400 ex-Oncology • 225+ Private Co’s
CONFIDENTIAL 5
6. RM Market: Expanding Rapidly
Dramatic Cell Therapy Revenue Growth
CTI Revenues: $410M (2008) - $5.1B (2014)"
Cell Therapy Industry: Billion Dollar Global Business With Unlimited Potential; "
Regenerative Medicine; Chris Mason, David Brindley, Emily J Culme-Seymour & Natasha L Davie"
CONFIDENTIAL 6
7. Global Company Distribution
Canada UK
24 firms 133 firms Europe
(ex. UK)
3% 19%
14% 93 firms
Asia
56% 2% 32 firms
5%
Middle East
17 firms
USA
386 firms
600+ RM companies worldwide!"
CONFIDENTIAL 7
8. RM Has Made Great Progress, but…
….Challenges Remain
R&D Manufacturing
§ Creation And Characterization Of § Technologies For Scale-up
Optimal Cells For Therapy - Safe & Reliable Expansion
– Controlling Differentiation Pathways
- Sterility Testing & Validation
§ Standards For The Field - Process Control & Reproducibility;
– What is an iPS Cell? …or MSC? Consistent Lots
- Closed Systems
§ Contaminant Free Cell Lines
§ Product Characterization
§ Safe & Reliable Expansion
– Safety; Identify; Potency
§ Track Cell Migration & Engraftment
§ Process Control : Process Is The
- Imaging Technology And Product
Biological Markers
– COGS; QC; & cGMP
§ Immune Modulation
§ Centralized Vs. Point Of Care
CONFIDENTIAL 8
9. …A Few More Challenges
Regulatory& IP Landscape Business Issues
§ Regulatory Environment Needs § Business Model Questions
Clarity - Capital Efficient R&D
- Standards & Guidelines Are Evolving
- Product V. Service Models
- Characterization
- Autologous V. Allogeneic
- Safety / Efficacy / Consistency
- Cross Border Inconsistencies
§ Reimbursement Issues
- Cost Savings Justification
§ IP Landscape Is Treacherous :
“Patent Thicket” § Sales & Marketing
- Fragmented Ownership; - Complex Channel Arrangements
- Patents Proliferating Rapidly : 25% GAGR
- Define Marketable “Product”
- Inconsistent & Competing Patents: Invites
Litigation - Educate Consumers Re: New Treatment
Paradigms
- Need “Freedom To Operate” Opinions
CONFIDENTIAL 9
10. RM Business Models: Autologous v. Allogeneic
Autologous Model Allogeneic Model
Patients Own Cells/Tissue Universal Cells in a Bottle
• Personalized Medicine • Big Pharma “Drug Model”
Advantages:
• Autologous Treatment for Prostate
Advantages:
Cancer Using Dendritic Cells
• Easier Regulatory Path • Scalable
(GTP) -Centralized Processing
• Low COGS
• No Immune Response
• $93K per Treatment Challenges:
Challenges:
-$1B+ Projected Revenues Regulatory
• More Difficult
• Difficult to Scale Path
• High COGS• $5.0B Market Cap (Until Aug 3,Response
• Immune
2011)
Service vs. Product"
CONFIDENTIAL 10
11. Agenda
I. The RM Market Is Entering A New Era
§ RM Has Made Great Progress
§ But Serious Commercialization Challenges Remain
II. New Economic Realties
§ A Fundamental Shift in Biotech Economics
§ The Valley of Death Is Expanding
§ A New Capital Efficient Model Is Required
II. The Role of RM Translation Centers
§ Enabling Capital Efficient RM Technology Development
§ Facilitating Collaborations in RM Technology Development
§ The RMC: An International Coalition of RMTCs
CONFIDENTIAL 11
13. Dendreon is a Success Story, But….
…Also a Cautionary Tale
August 3, 2011 "
"
"
Dendreon plunges 67% on slow sales, plans 'across the board'
layoffs"
"
Dendreon slashed its sales forecast for 2011 Wednesday "
after reporting lower than expected second-quarter net revenue of $49.6 million."
August 18, 2011 "
"
"
Biotech Stocks Battle The ‘Dendreon Effect’"
Company’s Troubles With Provenge Chill Fellow Drug Makers"
"
CONFIDENTIAL 13
14. Biotech Product Development Is
"Dependent on External Funding "
Probability: Probability: Probability:
Probability" 66%" 70%" 40%"
of success"
Steps Basic & Discovery Preclinical" Preclinical" Clinical" Clinical" Clinical"
Market"
" Research" Research" Development" Phase I" Phase II" Phase III"
1-3 years" 1.4-1.8 year" 2.5-3.8 years"
Outcome" Proof of Concept." Therapeutic IND" Safety" Efficacy" Product
Candidate" Release"
Investment"
PI" PII" PIII" $75=100MM"
Amount" $5-10MM"
$10-15MM" $20-25MM" $50-75MM"
Actors" Grants to Universities & Venture Investments" IPO & Partnering Deals"
Research Institutes,"
• Average Time to Market: 10-15 Years"
• Average Costs: $1B"
Key Metrics:" • Failure Rate: @90%"
• Less than 30% of approved drugs recoup
development costs"
CONFIDENTIAL 14
15. Venture Capital:
VCs Want “Pristine Deals”
Proprietary Commercial Technology Defensible Business Model
§ Great Science ≠ Great Business § Capital Efficient Tech Development
§ Proof Of Concept Established § Application Engines
§ Phase II Clinical Data § Project Based Models
§ Virtual Operations
Strong Management Team
§ Board Differentiation
§ SAB § How Is Your Approach Different?
§ Why Is It Better?
Solid Intellectual Property Position
§ Freedom To Operate Exit Strategy
§ Defensible IP (Patents & Trade § M&A: Attractive Products For Acquirer
Secrets) § Realistic Timeframe
Large Market Opportunity
Acceptable Risk/Return Profile
§ Target markets > $1B/year
§ Multiple Chances To Win
CONFIDENTIAL 15
16. Public Capital Markets:
Financing Alternatives
Key Strategies: IPO - 2ndary - Shelf Registration - PIPE
Company sells registered shares under an effective shelf registration statement (or a
Follow-On
specific registration statement) to public investors after a traditional 2 to 5 day
(Fully Marketed)
roadshow
At-the-Market Company sells registered shares under an effective shelf registration statement to
(ATM) investors into the general trading market over an extended period of time
SEC Registration
Required Upfront
Underwritten
Company sells registered shares under an effective shelf registration statement to
Equity Registered Direct
public investors after a 1 to 3 day confidential roadshow
(URD)
Registered Direct Company sells registered securities under an effective shelf registration statement to
(RD) a targeted group of institutional investors on a confidential basis
Company sells unregistered shares to a targeted group of institutional investors in a
Common Stock
private placement and files to register the securities typically within 30 days after the
PIPE
offering
No Upfront SEC Company sells unregistered convertible preferred stock/convertible debt to a
Convertible
Registration targeted group of institutional investors in a private placement and files to register
PIPE
Required the securities typically within 30 days after the offering
Convertible
Preferred/Debt
Company sells unregistered convertible debt securities to institutional investors in a
Rule 144A
Rule 144A offering and files to register the securities typically within 90 days after the
Convertible Debt
offering (public style execution)
[Source: Robin Smith – NeoStem]"
Public Transactions Private/Quasi-Public Transactions
8
CONFIDENTIAL 16
17. The Old “Relay” Model Is Very Capital
Intensive
Strategy: Build Company Toward An IPO
Business Models:
• “Platform” Company
• Develop technology horizontally across many therapeutic applications
• High research cash burn
• Large R&D staff
• “Product” Company (Specialty Pharma)
• Apply technology to specific therapeutic applications
• Multiple clinical programs
• Large clinical trial burn rate
Pre-IPO Capital: @
$90M"
IPO Metrics:
• Lead Program in late stage development
• Additional “shots on goal” (earlier clinical programs, or platform technologies)
• Substantial infrastructure (“bricks & mortar” & staff)
CONFIDENTIAL 17
18. The New Economic Reality
Traditional Capital Sources Are Unavailable
Public Markets: Closed?
• Biotech IPO Performance: Very Poor
• 2003-2007 Window: 77 Companies
• Average VC Return = 1.9X
• Oct 2007 (Market Peak): 59% trading below initial PPS
• June 2009: 79% trading below initial PPS
• 69% Trading Below Total Invested Capital
• Only 13 Biotech IPOs in the last 24 months; All Performed Poorly* (Reduced
Capital Raised; Reduced Offering Price; Trading Below IPO price)
Private Equity: Dramatically Reduced
• Venture Investments in Biotech are Down 45+%
• Back to pre=1990s level of capital (PWC Survey)
• VCs have fled Early Stage investments
• First-Time Financings at Some of the Lowest Levels in 40 Years
CONFIDENTIAL 18
21. Funding Sources: Government Funds
UK & EU Development Funds: MRC; Framework 7; European Research
Council
Traditional US Government Funding Increasing
§ NIH Funding & DARPA
Non-Traditional US Government Funding Is Available
§ DoD RM Initiate: AFIRM (Armed Forces Institute of Regenerative
Medicine)
§ HHS Initiative: BARDA (Biomedical Advanced Research and
Development Authority)
State RM Funds: CIRM Actively Funding ($1.2BM); Many Other US States
Other Regional Development Funds: Singapore EDB/Bio*One Fund; UK
Matching Grants; Gulf; India
§ Tech Transfer; Develop Biotech Industry
CONFIDENTIAL 21
22. The Valley of Death Is Expanding
Institutional Funding Is Not Readily Available
Until Phase 2 Trials
2-3 years 2-3 years 3-4 years
RESEARCH DEVELOPMENT CLINICAL TRIALS
(Phase 1 and 2)
“Valley of Death”
VC Investments
Grants & Seed
Available
Money
CONFIDENTIAL 22
23. “It’s a Very Tough Environment”
Many Biotech Companies in Peril
25% of All Biotech Companies have Failed since 2007
Delistings & Bankruptcies in 2008
• 22 Public Companies were Delisted from NASDAQ
• 214% increase over 2007 (7 Companies)
• 6 Public Companies filed for Bankruptcy Future Losses: "
• 200% increase over 2007 ( 2) @5% will Fail in Next
12-18 months "
Biotech Casualties in 2009:
• 44 Public Companies Lost (Delistings; M&A; BKs)
Cash Shortfalls (Oct 2010)
• 25% (73) Public Companies have less than 6 months cash
• Better than Dec 2008: 45% of Public Co’s Had Cash
Shortfall
CONFIDENTIAL 23
24. “It’s a Very Tough Environment”
" " " " " " November 14, 2011!
"
"
Geron Halting Stem Cell Research, Laying Off
"
Staff, Stem Cell Pioneer Exits Field
Geron exiting such research, laying off staff, to focus on
cancer drug tests!
!
MENLO PARK, Calif. (AP) -- Money troubles have forced the first company doing a government-
approved test of embryonic stem cell therapy to discontinue further stem cell programs and lay off much
of its staff. "
" " " ">>>>>>>"
In a statement, the company said the decision to narrow its focus "was made after a strategic review of
the costs, ... timelines and clinical, manufacturing and regulatory complexities associated with the
company's research and clinical-stage assets.". "
!
"
CONFIDENTIAL 24
27. A New Model Is Required:
Capital Efficiency Is Critical
CAPITAL EFFICIENCY: DO MORE WITH LESS
Extend Technology Development In Academic Setting
• Thru Phase II
Pursue Alternate Funding Sources
• Government Grants (NIH, DARPA, BARDA; Regional Development Funds;
Foundations & Disease Advocacy Groups; Partner with Pharma/Big Bio
Focus & Conserve Resources
• Focus On Core Business & Projects
• Reduce Infrastructure & Staffing
• Outsource Clinical Development (CRO; RMTs) & Manufacturing (CMO )
Collaborate & Share Resources
• Open Innovation Model
• Share Facilities, Technologies, Staff & IP Resources
CONFIDENTIAL 27
28. A New Model Is Required:
Capital Efficiency Is Critical
CAPITAL EFFICIENT BUSINESS MODELS
Virtual Company
• Outsource Clinical Development To RMTC or CRO
• Outsource Manufacturing To CMO
• Reduce Infrastructure & Staffing
• Project Based - POC Model
• Fund Specific Projects/Clinical Programs - Focus On Most
Compelling Therapeutic Application
• Create & Fund Company Post-POC Data
• Partnering Model
• Collaborative R&D
• Shared Facilities, Staff, IP, and Other Resources
CONFIDENTIAL 28
29. Agenda
I. The RM Market Is Entering A New Era
§ RM Has Made Great Progress
§ But Serious Commercialization Challenges Remain
II. New Economic Realties
§ A Fundamental Shift in Biotech Economics
§ The Valley of Death Is Expanding
§ A New Capital Efficient Model Is Required
II. The Role of RM Translation Centers
§ Enabling Capital Efficient RM Technology Development
§ Facilitating Collaborations in RM Technology Development
§ The RMC: An International Coalition of RMTCs
CONFIDENTIAL 29
30. The Role of RM Translation Centers:
Enabling Capital Efficient Technology Development
RM Translation Centers Offer
• State of the Art Facilities
- cGLP & cGMP Compliant
- Focused on Specific RM Technologies
• Access Deep Domain Knowledge in RM
– Core Expertise in Associated Academic Institution
– History of Collaboration
• Clinical Development Expertise
– Preclinical Thru Phase II
• Experienced Support Services
– Incubator/Accelerator
CONFIDENTIAL 30
31. The Role of RM Translation Centers:
Enabling Capital Efficient Technology Development
Collaborative Research Leveraging Shared Resources
RM Translation
Centers
• GLP/GMP Facilities
• RM Expertise
• Clinical Development
Experience
Pharma
Funding Sources
New RM Venture • Clinical
• Profit - Virtual Co Development
• Non-Profit • Manufacturing
- POC Project
• Marketing
• Government - Application Engine
• Reimbursement
Open Innovation, Henry Chesbrough ,
CONFIDENTIAL 31 Harvard Business School Press, 2006 "
32. The Role of RM Translation Centers:
Enabling Capital Efficient Technology Development
RM Translation Centers
CONFIDENTIAL 32
33. The Role of RM Translation Centers:
Enabling Capital Efficient Technology Development
RM Translation Centers
UCI Stem Cell Research Center"
Clinical Cell and Vaccine
Production Facility"
USC & UCSF RM Centers "
CONFIDENTIAL 33
41. Funding Sources: Corporate & Non-Profit
Philanthropic Foundations & Disease Advocacy Groups Provide Funding
§ JDRF; Michael J. Fox Foundation, CNS Foundation
§ Stowers Institute
Corporate Venture Groups
§ JJDC (Tengion; NovoCell)
§ Pfizer; NovoNordisk; GE Healthcare; Genzyme
Creative Sources of Funds:
§ Out license non-core technology
§ Provide consulting or lab services to generate cash flow
§ Work with a strategic partner
§ Biotech, Pharma & Device Companies
§ Merge with a cash rich company that is tech poor
CONFIDENTIAL 41
42. RM IP Landscape: A Patent Thicket
Key Patent Metrics (1980-2005)
Substantial Activity RM
Patents
Granted
• Patent Applications: 10,000+
• Patents Granted: 2,200+
US:
51%
Dramatic Increase in Filings Since 2000
• Over 25% Annual Growth Rate UK:
4%
Geographic Patent Distribution: US Dominates Canada:
4%
• US: Over 50% of Patents
• UK, Canada, Germany: @4% Each Germany:
• Australia, Japan, China, Israel: @3% 4%
Each Australia:
3%
Top 50 Patents Cover Core Technologies
• Cell Lines; Media; Differentiation
CONFIDENTIAL 42
43. RM IP Landscape: A Patent Thicket
Key US RM Patent Metrics
"
§ Unusual Patent Distribution"
- 44% Public Sector Entities "
- 56% Private Sector"
"
§ Fragmented Ownership"
- No Company Owns More Than
3% of Granted Patents "
§ Pharma & Big Bio Are Key Holders "
- Amgen, Novartis, Pfizer &
GSK "
§ Osiris, STEM, & Geron Have Large
Estates" *Only 3% of All USPTO Patents
" Are Held By Public Entities"
"
CONFIDENTIAL 43
44. Funding & Commercialization Strategies for
Regenerative Medicine Companies
Gregory A. Bonfiglio
Proteus Venture Partners"
November 15, 2011 "